OptimizeRx Corporation Common Stock

OPRX

OptimizeRx Corporation (OPRX) is a digital health company that provides a platform connecting healthcare providers and pharmaceutical companies. It delivers real-time, point-of-care communication solutions aimed at improving patient outcomes by streamlining the delivery of medication information, reimbursement support, and adherence programs within the healthcare ecosystem.

$11.65 -0.31 (-2.59%)
đźš« OptimizeRx Corporation Common Stock does not pay dividends

Company News

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
GlobeNewswire Inc. • Optimizerx Corp. • December 17, 2025

OptimizeRx Corp. announced four new partner agreements expanding its point-of-care network, increasing National Provider Identifier (NPI) reach by 37% through exclusive partnerships with e-prescribing platforms and health systems access partners.

OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
GlobeNewswire Inc. • Optimizerx Corp. • March 11, 2025

OptimizeRx Corp. has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.

Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research • Zacks.Com • August 1, 2024

Smith Micro Software, Inc. reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a loss of $0.35. The company's revenue of $5.14 million also missed estimates. The stock has lost about 62.9% since the beginning of the year.

New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
GlobeNewswire Inc. • OptimizeRx Corporation • June 20, 2024

• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client

Expert Ratings For OptimizeRx
Benzinga • Benzinga Insights • May 15, 2024

OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Ind...

Related Companies